Lung Cancer

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

By

A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

By

Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

By

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

High-Dose Vitamin C Infusions Increase Cancer Cell Sensitivity to Chemotherapy, Radiation

High-Dose Vitamin C Infusions Increase Cancer Cell Sensitivity to Chemotherapy, Radiation

By

Regular infusions of high doses of vitamin C safely increased cancer cell sensitivity to treatment in patients with brain and lung cancers.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

By

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

Radiation Therapy for Locally Advanced NSCLC Linked to Cardiac Events

Radiation Therapy for Locally Advanced NSCLC Linked to Cardiac Events

By

Risk for cardiac events linked to RT for locally advanced NSCLC, especially in patients with a history of cardiac disease or receiving higher RT doses.

CTCs Promising as Biomarker to Identify Lung Cancer Recurrence

CTCs Promising as Biomarker to Identify Lung Cancer Recurrence

By

Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.

Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations

Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations

By

A free lung cancer screening program in Augusta, Georgia, found more than double the lung cancer rate of previous screenings.

Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions

Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions

By

Patients were more comfortable with their decisions about lung cancer screening after a shared decision-making visit.

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

By

Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.

Nasal Biomarker in Smokers Could Predict Lung Cancer

Nasal Biomarker in Smokers Could Predict Lung Cancer

By

Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.

Proportion of Never-Smokers With NSCLC Is on the Rise

Proportion of Never-Smokers With NSCLC Is on the Rise

By

A study of a large, diverse patient population appears to show an increasing incidence of lung cancer in patients who have never smoked tobacco.

Patients with Lung Cancer Do Not Benefit from Statins

Patients with Lung Cancer Do Not Benefit from Statins

By

Statins provide no benefits, or adverse effects, in patients with lung cancer, according to a phase 3 trial.

Risk of Lung Cancer Increases After Radiation for Breast Cancer

Risk of Lung Cancer Increases After Radiation for Breast Cancer

By

Treatment with radiation therapy for invasive breast cancer may place East Asian women at a greater risk of developing second primary lung cancer (SPLC).

NSCLC: Pathway Navigation Program Lowers Costs of Care

NSCLC: Pathway Navigation Program Lowers Costs of Care

By

A clinical pathways navigation program for patients with non-small cell lung cancer significantly reduced cost of care while preserving clinical outcomes.

FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC

FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC

By

Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use

E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use

By

E-cigarettes and replacement nicotine therapy deposit fewer harmful chemicals in the body that smoking.

Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments

Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments

By

Elderly with NSCLC have lower incidence of esophagitis, can tolerate aggressive radiation therapy.

Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods

Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods

By

Annual lung cancer screening of only high-risk smokers more cost-effective than current methods.

Lung Cancer Screening Rates Low Among Present and Former Smokers

Lung Cancer Screening Rates Low Among Present and Former Smokers

Researchers estimate that out of the 6.8 million current and former smokers eligible for lung cancer screening in 2015, only a fraction received it.

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

By

There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.

Nut Consumption Inversely Associated With Lung Cancer Risk

Nut Consumption Inversely Associated With Lung Cancer Risk

By

A higher consumption of nuts was associated with a lower overall risk for developing lung cancer irrespective of smoking status.

Many VHA Patients Eligible for Lung Cancer Screening

Many VHA Patients Eligible for Lung Cancer Screening

Second study shows increase in lung cancer screening from 1.3 to 2.1 percent from 2010 to 2015

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

By

The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.

Use of Upfront TKIs Linked to Inferior OS in EGFR+ NSCLC With Brain Metastases

Use of Upfront TKIs Linked to Inferior OS in EGFR+ NSCLC With Brain Metastases

By

Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

By

Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.

Many Advanced NSCLC Patients Not Getting Helpful Treatment

Many Advanced NSCLC Patients Not Getting Helpful Treatment

Study found 21 percent of those with late-stage non-small cell lung cancer went without therapy, even though it could boost survival.

Tobacco Counseling for Youth, Adults Reduces Smoking Prevalence

Tobacco Counseling for Youth, Adults Reduces Smoking Prevalence

Annual counseling could reduce prevalence and prevent many smoking-attributable fatalities.

No Differences in Lung Cancer Mutations Between White, Black Patients

No Differences in Lung Cancer Mutations Between White, Black Patients

By

Analyses of lung tumor specimens were used to determine whether mutational profiles of lung cancers differ between black and white patients. Such differences could explain differences in prognosis and lead to reductions in outcomes disparities.

Lung Cancer Navigator App Aims to Help Patients Understand Disease

Lung Cancer Navigator App Aims to Help Patients Understand Disease

By

Lung Cancer Navigator, a mobile, customizable app from LUNGEVITY, helps patients with lung cancer better understand their disease, manage medications, track symptoms, and access support.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs